Keybanc Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $12
Keybanc Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $12
Keybanc維持對Recursion Pharmicalsion的增持，將目標股價下調至12美元
Keybanc analyst Scott Schoenhaus maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price target from $16 to $12.
Keybanc分析師Scott Schoenhaus維持對Recursion Pharmaceuticals (NASDAQ:RXRX)的超配，將價格目標從16美元下調至12美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。